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Cohen–Gibson syndrome is a rare genetic disorder, characterized by fetal or early
childhood overgrowth and mild to severe intellectual disability. It is caused by hetero-
zygous aberrations in EED, which encodes an evolutionary conserved polycomb
group (PcG) protein that forms the polycomb repressive complex-2 (PRC2) together
with EZH2, SUZ12, and RBBP7/4. In total, 11 affected individuals with heterozygous
pathogenic variants in EED were reported, so far. All variants affect a few key resi-
dues within the EED WD40 repeat domain. By trio exome sequencing, we identified
the heterozygous missense variant c.581A > G, p.(Asn194Ser) in exon 6 of the EED-
gene in an individual with moderate intellectual disability, overgrowth, and epilepsy.
The same pathogenic variant was detected in 2 of the 11 previously reported cases.
Epilepsy, however, was only diagnosed in one other individual with Cohen–Gibson
syndrome before. Our findings further confirm that the WD40 repeat domain repre-
sents a mutational hotspot; they also expand the clinical spectrum of Cohen–Gibson
syndrome and highlight the clinical variability even in individuals with the same path-
ogenic variant. Furthermore, they indicate a possible association between Cohen–
Gibson syndrome and epilepsy.
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1 | INTRODUCTION
EED encodes an evolutionary conserved polycomb group (PcG) pro-
tein. Together with EZH2, SUZ12, and RBBP7/4, this protein forms
the polycomb repressive complex-2 (PRC2) (Ciferri et al., 2012;
Imagawa et al., 2017; Margueron & Reinberg, 2011). PRC2 is a con-
served multiprotein chromatin complex important for maintaining
transcriptional gene repression and plays a crucial role in the develop-
ment and eukaryotic cellular identity, stem cell maintenance, and tis-
sue homeostasis (Glancy et al., 2020; Sauvageau & Sauvageau, 2010).
Its trimeric core consisting of SUZ12, EED, and EZH1/2 is sufficient,
together with RBBP4/7, to catalyze monomethylation, dimethylation,
and trimethylation of histone H3 at lysine residue 27
(H3K27me1/2/3) (Glancy et al., 2020; Imagawa et al., 2017). EED
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contains seven-bladed β-propeller WD40 domains (Montgomery
et al., 2007), disruption of which resulted in impaired interaction
between EED and EZH2 (Denisenko et al., 1998; Spellicy et al., 2019).
Pathogenic variants, which lead to an exchange of amino acids
in EED were implicated in Cohen–Gibson syndrome (COGIS,
OMIM# 617561). So far, eight individuals with de novo pathogenic
variants and three further cases with one parent missing for segre-
gation analysis were reported (Cohen et al., 2015; Cohen &
Gibson, 2016; Cooney et al., 2017; Griffiths et al., 2019; Imagawa
et al., 2017; Smigiel et al., 2018; Spellicy et al., 2019; Tatton-Brown
et al., 2017). All presented with fetal or early childhood overgrowth
and with mild to severe intellectual disability. Other frequent clini-
cal features included cardiac (mitral valve regurgitation, persistent
ductus arteriosus, atrial septal defect, ventricular septal defect,
murmur), skeletal (scoliosis, cervical spinal canal stenosis,
camptodactyly), ophthalmological (myopia, strabismus, cataract,
chorioretinitis), genitourinary (cryptorchidism, nephromegaly,
duplex kidney), and dermatological abnormalities (abnormal pig-
mentation, nevi, capillary hemangioma or thin and fragile skin).
Other findings in a few affected individuals, respectively, were
endocrine anomalies (hyperinsulinemia and hypoglycemia), hernias,
bifid uvula, Hirschsprung's disease, constipation or diarrhea, dys-
plastic enamel, tracheomalacia, bruxism, lipodystrophy, Willebrand
disease, and hearing loss. While cerebral magnetic resonance imag-
ing (MRIs) were reported to be normal in the majority of affected
individuals, for example, abnormal corpus callosum and septum
pellucidum cysts were reported in a few (Cohen et al., 2015;
Cohen & Gibson, 2016; Cooney et al., 2017; Griffiths et al., 2019;
Imagawa et al., 2017; Smigiel et al., 2018; Spellicy et al., 2019;
Tatton-Brown et al., 2017).
Of note, also EZH2 and SUZ12 are implicated in overgrowth syn-
dromes. Variants in EZH2 are associated with Weaver syndrome
(WVS, OMIM# 277590) and variants in SUZ12 with Imagawa–
Matsumoto syndrome (IMMAS, OMIM# 618786). Although the
affected proteins belong to the same polycomb repressive complex,
the associated disorders show some differences in clinical presenta-
tion. While overgrowth is common in all COGIS, WVS, and IMMAS,
intellectual disability is more frequent in individuals with COGIS
(Spellicy et al., 2019) or WVS than in individuals with IMMAS (Cyrus
et al., 2019; Imagawa et al., 2018). Epilepsy and seizures were
reported mainly in individuals with WVS (Gibson et al., 2012; Kamien
et al., 2018) and only in a single patient with IMMAS (Imagawa
et al., 2018) or COGIS, respectively (Cohen et al., 2015). While many
overgrowth syndromes are associated with an increased risk for
tumors (Kamien et al., 2018), this seems to be low for WVS (Tatton-
Brown & Rahman, 1993) and so far not evident for IMMAS (Cyrus
et al., 2019) or COGIS (Griffiths et al., 2019; Imagawa et al., 2018).
We now report on an adult individual with Cohen–Gibson syn-
drome harboring the heterozygous, recurrent missense variant
c.581A > G, p.(Asn194Ser) in exon 6 of EED and presenting with epi-
lepsy as an additional clinical feature. Our findings confirm the WD40
repeat domain as a mutational hotspot and suggest that also seizures
might be a clinical aspect of Cohen–Gibson syndrome.
2 | CLINICAL REPORT
The reported male individual is the only child of non-consanguineous
healthy parents of European origin. Pregnancy was uneventful. He
was born by cesarean section due to umbilical cord wrapping in gesta-
tional week 38 with normal growth parameters (weight 3840 g (+1.22
SD); length 53 cm (+0.83 SD); head circumference 36 cm (+0.79 SD)).
While motor development was unremarkable with walking at age of
14 months, severely delayed speech development was noted. He was
only able to speak short sentences at age 6–7 years. Through speech
therapy, he caught up well on his speech and language skills and is
now able to speak full sentences. Moderate intellectual disability was
diagnosed (no formal test available). He attended a school for children
with special needs and now lives and works in a sheltered environ-
ment. At age of 5 years, absence epilepsy was diagnosed, which
responded well to treatment with ethosuximide with subsequent
occurrence of occasional seizures, only. At age of 13 years, focal, sec-
ondary generalized seizure with tonic–clonic convulsions, salivation,
and loss of consciousness occurred. Because of secondary generaliza-
tion, anticonvulsive treatment was changed to valproate. At age of
15 years, a grand-mal episode with three seizures in a row occurred.
Subsequent EEG showed isolated right, pseudofocal, partly bifrontal
spikes compatible with generalized epilepsy. Reduced Factor VIII and
von-Willebrand-factor were noted in routine testing and considered
as potential side effects. Thus, treatment was successively tapered
and substituted by lamotrigine. Subsequently, the patient remained
seizure-free. Behavioral abnormalities such as aggressive episodes
toward his family were reported during adolescence, co-occurring
with antiepileptic treatment change from ethosuximide to valproate.
Due to suspicion of a schizoaffective disorder, the patient was tempo-
rarily treated with olanzapine and promethazine, which, however,
were discontinued due to dizziness. Social behavior as a young adult
and after moving into a sheltered accommodation was adequate. MRI
was unremarkable apart from a possible microadenoma in the poste-
rior lobe of the pituitary gland. An echocardiographic examination
showed a discreet mitral valve prolapse. At latest physical examination
at age 21 years, his height was 2.02 m (+3.12 SD), weight was 80 kg
(body mass index 20), and he was macrocephalic with a head circum-
ference of 61 cm (+2.64 SD). Multiple nevi all over the body and
molluscae contagiosae on both hands were noted. He had myopia.
Subtle facial dysmorphism included a triangularly shaped face, large
and low set ears, hypertelorism, a prominent philtrum, a horizontal
chin crease, and retrognathia. Furthermore, scoliosis, long fingers,
large feet, and a funnel chest were noted. Behavior and language
appeared adequate.
Due to the combination of tall stature, cardiac and skeletal anom-
alies, Marfan syndrome (MFS, MIM# 154700) was initially suspected,
and testing of FBN1 was initiated. This, however, did not detect any
pathogenic variant. Conventional karyotyping and chromosomal
microarray analysis did not show pathogenic aberrations, either, apart
from a maternally inherited 4.5 kb heterozygous deletion in 3q27.1
(chr3:182755006–182759538). This deletion is harboring the
MCCC1-Gen (NM_001293273:e8-10del). Autosomal recessive
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variants in MCCC1 are associated with 3-methylcrotonyl-CoA carbox-
ylase 1 deficiency (MCC1D, MIM# 210200). However, there was no
single nucleotide variant on the other MCCC1-allele detectable by
exome sequencing. Trio exome sequencing on a HiSeq 2500 platform
(Illumina) after enrichment with TWIST Human Core Exome Enrich-
ment Technology (TWIST Bioscience) revealed a de novo heterozy-
gous missense variant (c.581A > G, p.(Asn194Ser)) in exon 6 of EED
(NM_003797.3). This variant has been reported in two other individ-
uals before (Griffiths et al., 2019; Spellicy et al., 2019) (Table 1). Since
seizures do not appear to be a consistently reported clinical feature in
Cohen–Gibson syndrome, we specifically searched for additional vari-
ants in epilepsy-associated genes in the exome data. This revealed
only a heterozygous variant c.11397G > C, (p.(Gln3799His)) of
unknown significance in ADGRV1 (NM_032119). To date, a variant in
this gene was only detected in a single family with febrile seizures
(OMIM# 604352). The identified variant in ADGRV1 in our patient
was furthermore inherited from the healthy father, thus likely being a
polymorphism.
Written informed consent and consent to publish mutational and
clinical details were obtained from the mother as legal guardian.
3 | DISCUSSION
The reported individual carrying the p.(Asn194Ser) variant in EED
showed typical clinical aspects of Cohen–Gibson syndrome such as
overgrowth, moderate intellectual disability, speech delay, cardiac
abnormalities (mitral valve prolapse), and facial dysmorphism
(Figure 1). Additionally, he presented with epilepsy, which is not a typ-
ical or frequent aspect of Cohen–Gibson syndrome. So far, seizures
were only reported in two individuals with pathogenic variants in EED
(Cohen et al., 2015; Griffiths et al., 2019). Confirmed epilepsy with
irregular wave pattern in the EEG, manifesting at age 4.5 years was
diagnosed in one individual with the p.(Arg302Ser) variant in EED
(Cohen et al., 2015). EEG abnormalities were responsive to phenytoin
and primidone (Cohen et al., 2015). Another individual, carrying the
same p.(Asn194Ser) variant as the herewith reported individual, devel-
oped seizures at age of 8 years (Griffiths et al., 2019), which, however,
were later attributed to hyperinsulinemic hypoglycemia (Griffiths
et al., 2019).
Downregulation of H3K27me3 plays an essential role in neuro-
genesis and development of the brain (Akizu et al., 2010) as well as in
seizure susceptibility by regulating the expression pattern of febrile
seizure-related genes DPP4 (OMIM#102720) and IL6 (OMIM#147620)
(Wang et al., 2017). Also, H3K27me3 was progressively downregulated
during epileptogenesis in rat hippocampus (Zybura-Broda et al., 2016).
A role in epileptogenesis of the EED interactor and H3K27me3
methylation co-regulator EZH2 is already evident by the occurrence
of seizures in individuals with Weaver syndrome (Gibson et al., 2012;
Kamien et al., 2018) and functionally by its ability to regulate differen-
tially expressed genes across multiple rodent models of acquired epi-
lepsy (Khan et al., 2019). Therefore, EED variants might also
contribute to epileptogenesis, resulting in the occurrence of seizures
as an infrequent aspect of Cohen–Gibson syndrome. Better future
estimates on frequency and penetrance of epilepsy within Cohen–
Gibson syndrome might be possible based on larger numbers of
affected individuals.
The identified missense variant p.(Asn194Ser) in the WD40
repeat 3 is located in the H3K27me3 binding pocket of the EED pro-
tein (Spellicy et al., 2019). All pathogenic variants in EED identified so
far are located in a mutational hotspot altering amino acids in or near
the WD40 repeats 3 to 5 (Cyrus, Burkardt, et al., 2019; Griffiths
et al., 2019; Spellicy et al., 2019). A reduced PRC2 methyltransferase
activity was demonstrated in a lymphoblastoid cell line derived from
an individual with the p.(Arg236Thr) mutation in EED (Imagawa
et al., 2017) and for several other EED variants (Lee et al., 2018). It
was speculated that variants in mutational hotspots specifically impair
the interaction between EED and the EZH2-SRM domain and thus
result in reduced PRC2 function (Spellicy et al., 2019). Such a residue-
specific consequence is supported by the observation of recurrent
TABLE 1 Clinical variability within
three individuals with the recurrent p.
(Asn194Ser) EED-variant
Current report Griffiths et al. (2019) Spellicy et al. (2019)
EED: c.581A > G, p.(Asn194Ser)
Generalized overgrowth + + +
Intellectual disability “Moderate” “Mild” IQ 44
Scoliosis +  +
Dermatological abnormalities +  +
Genitourinary abnormalities  + +
Cardiac abnormalities +  +
Ocular abnormalities +  +
Abnormal MRI findings +  
Joint hypermobility +  
Hearing loss   
Epilepsy +  
Hypoglycemia/hyperinsulinemia  + 
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pathogenic missense variants at only four amino acids (Cohen
et al., 2015; Cohen & Gibson, 2016; Cooney et al., 2017; Griffiths
et al., 2019; Imagawa et al., 2017; Smigiel et al., 2018; Spellicy
et al., 2019; Tatton-Brown et al., 2017) and by the fact that despite a
high pLI score of 1 (o/e = 0.04 [0.01–0.19]) in gnomAD (Karczewski
et al., 2020), indicating intolerance to haploinsufficiency, no patho-
genic truncating variants in EED or pathogenic deletions of EED have
been reported, so far. The Decipher database (Firth et al., 2009) con-
tains two deletions with a size of 202.31 or 366.74 kb containing EED
and 4 or 6 neighboring genes. Both deletions are of unclear signifi-
cance, one of them being even maternally inherited.
The deleterious effect of the recurrent missense variants seems
to be homogeneous. No apparent genotype–phenotype correlation
could be delineated (Spellicy et al., 2019), and even between the
three individuals with the identical p.(Asn194Ser) variant a high clini-
cal variability was observed (Griffiths et al., 2019; Spellicy
et al., 2019).
This report raises the number of described individuals with Cohen–
Gibson syndrome to 12, with 5 being adults, (Cohen et al., 2015;
Cohen & Gibson, 2016; Cooney et al., 2017; Griffiths et al., 2019;
Imagawa et al., 2017; Smigiel et al., 2018; Spellicy et al., 2019; Tatton-
Brown et al., 2017). As the total number is still very small, further studies
and larger cohorts of individuals with EED variants will be required to
define the clinical spectrum and clinical variability.
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